LifetimeAward

11/20/2025

Second Strong AI summit was a success! AGI architecture was discussed by Legends of AGI, Professor Stephen Grossberg and Dr. Michael Levin, to name a couple of big names!

We incentivize the AGI development in multi-disciplinary cooperation →  best participants get 10k each, to merge with others and build "autonomous agentic systems" and AGI in definitions on Mustafa Suleyman. And investments from AGI Alliance will boost the AGI developed in AGI Prize.

11/20/2025

AGI Alliance founder Eduard Musinschi has delivered AGI Prize presentation at Futuristevent.com with leading UAE financial companies and Mastercard sponsoring it, see video of AGI Prize keynote

https://www.linkedin.com/feed/update/urn:li:share:7376583446682484736/

It was a fantastic Futuristevent.com with leading UAE financial companies and Mastercard sponsoring it, see video of my AGI Prize keynote https://lnkd.in/dzSC3xs6

08/13/2024

There is list of top speakers and agenda.
1.Winston Ma. He was Managing Director for China Investment Corporation (CIC), China’s sovereign wealth fund. Mr. Ma served as a vice president at J.P. Morgan. Keynoted at multiple AI Events and at FII INSTITUTE event in Miami 2024.

2. Steven Hoffman, CEO of Founders Space, ranked #1 accelerator for international startups by Forbes.
He is expert on AI business strategy to Qualcomm, Huawei, Alibaba, Bosch, Intel, Disney, Warner Brothers, Ad Age, MetLife, NBC, A&E, Siemens, Viacom,
https://www.foundersspace.com/hoffman/

3. Steve Hoffman and I will make Mastermind on AI unicorns (UiPath, PicsArt).

4. Gary Marcus, renowned AI author

5. Dr. Oullier is a PhD in neuroscience, an entrepreneur and investor in human-machine interfaces and models improving safety, performance Multimodal Cognitive AI Agents

6. Alwin Wang Graylin is President of HTC China, a renowned tech entrepreneur and executive, who has founded multiple startups in AI search, mobile platforms, social media, location-based services, and big data AI.

7. Dr. Adityo Prakash is CEO of AI healthtech unicorn Verseon.com
8. Bryan Talebi is the CEO and Co-founder at Ahura AI. He is a serial investor and has worked with NASA, Southwestern, Zocdoc, Sols, Bizzabo, Vestorly,

9. Dr. Peter Voss has coined the term AGI, he is an innovator, a serial entrepreneur, CEO, engineer and scientist. His life’s mission is to bring human-level AI to the world to optimize human flourishing.

10. Robin Rowe is consultant of the United Nations, WHO, Lenovo, AT&T, GoPro, DreamWorks Animation. Awarded Novartis Biome prize and multiple HeroX awards for AI and telecommunications. Architect of AI crisis detection at NORAD, communication software for U.S. traffic control, and for Disney and Mattel.

11. Salvador Paiz is billionaire Chairman of Grupo PDC, a Latin American conglomerate. He is Board Member of FUNDESA & Walmart, member of Forbes Nonprofit Council and Young Global Leader for World Economic Forum.

12. Mr. Bowdre the acting Chairman of the Miami-Dade County Digital Commission.

13. Arati Prabhakar, Advisor to President Biden on Technology.

14. Senator Ted Cruz.
Speakers from White House and Congress will open exclusive inside information on future of AI regulation

Also, we have CTO of Blackrock and other big companies, not speaking at main event but networking at VIP Party.

Email | Instagram | TikTok | Facebook | LinkedIn | YouTube Steven Hoffman (Captain Hoff) is an expert on AI business strategy and author of three award-winning books: “The Five Forces” …

08/13/2024

Fireside chat on Nvidia and Neom secrets, with Winston Ma, moderator of www.ownitmiami.com !

Each VC and founder should read his books! He was Managing Director for China Investment Corporation (CIC), China’s sovereign wealth fund. Mr. Ma served as a vice president at J.P. Morgan.

Latest books "The Hunt for Unicorns: How Sovereign Funds Are Reshaping Investment in the Digital Economy" and "The Digital War"



https://www.youtube.com/watch?v=tJiQkBbmt6g

Are you ready to explore the future of AI and robotics? We're thrilled to invite you to the Strong AI Summit on October 10th, 2024, in vibrant Miami, FL!📅 D...

08/06/2024

To keep up with market crashes, investors need "Emtech Rating", one of tentative outcomes of the Strong AI Summit.
Other outcomes are:
AI-enabled risk assesment tools
Networking with top global funds from 9 countries
Mastermind
Only 99 Early bird tickers

Strong AI summit and Ownit mastermind have joined forces to bring together the top lawmakers from the United States, Latin America, the Middle East, Europe, and Asia, along with leading companies in the AI and digital security space, industry professionals, VCs, family offices, private equity and so...

08/06/2024

Legendary Steve Hoffman and I will make Mastermind on AI unicorns (Uipath and Picsart we've used to consult),
for leading funds from Saudi Arabia and Americas, at Strong AI Ownit https://www.ownitmiami.com/

04/19/2024

Most active investor!
Report 2024

Friends of FJ Labs,

01/08/2024

Happy 60th Birthday to Nicolas Cage!
Almist 40 movies in 40 years long career. Longevity in profession = longevity in life

Happy Birthday to Nicolas Cage! 📸: Getty

09/07/2023

6 proven cancer therapies.
Cancer’s days are numbered and there’s good reason to believe we can cure it within the next 10 years.

Fast forward to today and a cascade of technological breakthroughs are creating unstoppable momentum in our fight against cancer. We can now attack cancer from a constellation of angles with treatments that are less toxic and, in many cases, far more effective than standard options.


Here are 6 of the most promising treatments for you to track.

Let’s dive in…

1. CHECKPOINT INHIBITORS
A recent breakthrough cancer study reported in The New England Journal of Medicine showed that treatment with the drug dostarlimab resulted in complete remissions of early-stage re**al cancers in every treated patient. I repeat—every treated patient.

Approved by the FDA in August last year, dostarlimab is a kind of cancer immunotherapy treatment referred to as a “checkpoint inhibitor.” The name comes from the fact that checkpoint inhibitors block (i.e., inhibit) the brakes (i.e., checkpoints) that tumors use to fend off our immune system’s T cells.

The first significant implication of this study is that checkpoint inhibitors can be applied to early-stage re**al cancers with incredible efficacy. Conceivably, this could eliminate the need for surgery, radiation, and chemotherapy one day—with immune memory preventing future cancer spread.

Additionally, the current re**al cancer standard of care requires surgery. If the cancer is too close to the a**s, patients need AP resections that require a colostomy bag for waste elimination. With checkpoint inhibition therapy, re**al cancer patients may now avoid this and drastically improve their quality of life.

2. PERSONALIZED CANCER VACCINES
If you were to closely examine the surface of a tumor cell, you would see that it’s bristling with unique proteins known as antigens. T cells produced by our immune system are deployed to detect and attach themselves to antigens on the surface of tumor cells. By doing so, these T cells kill tumor cells and prevent the spread of cancer.

Neoantigens are new antigens that are the result of mutations found only in tumor cells. Highly personalized vaccines known as neoantigen cancer vaccines are a novel approach being used to find the neoantigens on an individual patient’s tumor.

So, how does this work?

Scientists start by sequencing small bits of tumor obtained via a biopsy, looking for mutations that produce neoantigens. They then select for neoantigens that are abundant and most likely to attract T cells. These neoantigens are then synthesized in a lab and packed into a vaccine.

Over the course of several months, patients receive injections containing millions of these neoantigens specifically designed to bootstrap our immune system to produce T cells that attack these specific neoantigens and the tumor.

A number of these neoantigen vaccines are currently being developed in the treatment of triple-negative breast cancer, advanced melanoma, and lung non-small-cell cancer.

3. NATURAL KILLER CELLS HARVESTED FROM HUMAN PLACENTAS
You may have heard about chimeric antigen receptor (CAR) T-cell therapy. While a promising treatment for some patients, CAR T-cell therapy has sometimes been shown to incite disastrous immune responses—Cytokine Release Syndrome (CRS) being perhaps the most serious and well documented.

Meanwhile, a more robust and higher-endurance cousin of T cells is making waves in the fight against cancer. Known as natural killer (NK) cells, these immune system mercenaries have advantages over T cells in that they are less prone to some of CAR T-cell therapy’s side effects. And NK cells don’t have to come from the patient they’re trying to treat.

Dr. Bob Hariri and colleagues at Celularity are pioneering the use of NK cells from human placentas to combat cancer. Often regarded as a throwaway organ, placentas are actually packed with NK cells. In fact, placental NK cells may last twice as long as ordinary NK cells, secrete higher levels of enzymes that break apart tumor cells, and are armed with a toxic cocktail of proteins that kill tumor cells.

Optimism abounds after Celularity’s experimental NK-cell therapy, Taniraleucel, demonstrated considerable promise in lab mice injected with human brain cancer cells. Human clinical trials of Celularity’s specially formulated NK cells are currently in progress.

4. ECDNA TARGETED THERAPY
In 2019, scientists at UCSD observed circles of extrachromosomal DNA (ecDNA) that independently replicated outside of our chromosomes. As it turns out, ecDNA are found in more than half of all solid tumor types but are largely absent from healthy cells. They also possess the ability to replicate faster than normal DNA to drive cancer.

In a sense, these ecDNA circles are like canaries in the coal mine that warn against the presence of cancer.

Leading the pack is the company Boundless Bio, combining imaging and molecular analysis tools to exploit unique vulnerabilities in ecDNA circles. With enhanced genomic and mapping techniques elucidating the structure of these ecDNA circles, it is now harder for cancer to hide in plain sight and we now have additional targets that we can pinpoint and attack cancer with.

5. SYNTHETIC LETHALITY
Today, gene editing tools such as CRISPR are being paired with genomic data and machine learning algorithms to target problematic cancer gene pairs and knock them out utilizing the approach of synthetic lethality.

What differentiates synthetic lethality from other treatment methods in our list is that synthetic lethality is not a drug, but rather a novel treatment approach used to disable cancer.

Synthetic lethality refers to a new strategy for tackling hard to treat cancers. It is based on the dependency of two cancer genes on each other, where mutation of one gene is more likely to allow cancer cells to survive. However, mutation of both cancer genes at the same time will cause cancer cell death.

Our bodies possess genes referred to as “tumor suppressor genes.” The loss of tumor suppressor gene function—often by mutation—can turn normal cells into cancer cells. Targeting the gene partner of these genes that have lost tumor suppression function allows us to precisely target cancer cells.

You may have heard of the actress Angelina Jolie having preventative bilateral mastectomies because she carried the BRCA1 gene mutation. Interestingly enough, the BRCA1 gene is a key tumor suppressor gene and was found in the first synthetic lethal interaction.

Why does this matter?

When you consider the exponential number of potential synthetic lethal gene pairs in the human genome that we are now finding, this transformative precision medicine approach can now be implemented to track and terminate these troublesome gene pairs that communicate with each other and perpetuate the spread of cancer.

6. FOOD & OUR MICROBIOME